CCT245737 is primarily used in research settings as a potent and selective inhibitor of CHK1 (Checkpoint kinase 1). Its application is significant in the study of cancer biology, particularly in understanding the role of CHK1 in DNA damage response and cell cycle regulation. Researchers utilize CCT245737 to investigate its potential in enhancing the efficacy of chemotherapy and radiotherapy by disrupting the DNA repair mechanisms in cancer cells. This compound is also employed in preclinical studies to explore its therapeutic potential in various cancer types, especially those with defects in DNA repair pathways. Additionally, it aids in the development of combination therapies, where it is tested alongside other anticancer agents to assess synergistic effects.